吉西他滨对膀胱癌的有效性及安全性 Meta 分析

原文： 2022 年发布于 Urol Oncol 19 卷第 9 期 849929  浏览量：215次 原文链接

作者单位： Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria. Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz , 5166, Iran. Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck , 23562, Germany. Department of Urology, Semmelweis University, Budapest, 1082, Hungary. Department of Urology, Luzerner Kantonsspital, Lucerne , 6000, Switzerland. Department of Urology & Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan , 20132, Italy. Department of Urology, King Fahad Specialist Hospital, Dammam , 32253, Saudi Arabia. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany. Department of Urology, Weill Cornell Medical College, New York, NY 14853, USA. Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague , 15006, Czech Republic. Karl Landsteiner Institute of Urology & Andrology, Vienna , 1010, Austria. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman , 11942, Jordan.

归属分类：膀胱肿瘤治疗及预后证据

DOI： 10.7717/peerj.12248

关键词： Autoantigens Biomarkers Tumor/genetics/metabolism Gene Expression Regulation Neoplastic Humans Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase/genetics/metabolism Prognosis *Urinary Bladder Neoplasms/pathology Bladder cancer Meta-analysis Microarray datasets Overall survival Prognostic biomarker

目的系统分析评价国内非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术后灌注吉西他滨和吡柔比星治疗的有效性和安全性 . 方法检索建库至 2022 年 5 月 13 日 ,Cochrane Library 、 PubMed 、 EMbase 、中国知网、维普数据库和万方数据库中的随机对照研究 , 根据纳入和排除标准对其进行筛选 , 并提取相关信息进行 Meta 分析 . 结果最终纳入 23 项随机对照研究 . 结果显示 , 与吡柔比星比较 , 吉西他滨可显著降低术后 1 年内复发率〔 OR=0.46,95 ％ CI(0.32,0.67),P<0.0001 〕及术后 2 年累积复发率〔 OR=0.48,95 ％ CI(0.36,0.64),P<0.00001 〕 , 各研究间无显著异质性 (P=0.18,I2=25 ％ ;P=0.96,I2=0 ％ ). 安全性方面 , 吉西他滨总体不良反应少于吡柔比星〔 OR=0.34,95 ％ CI(0.22,0.53),P<0.00001 〕 , 各研究间存在较大异质性 (P=0.008,I2=52 ％ ). 结论与吡柔比星比较 , 吉西他滨更为安全、有效 .